Trial Profile
A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tenalisib (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Rhizen Pharmaceuticals
- 24 Sep 2020 According to a Rhizen Pharmaceuticals Media Release, Dr. Swaminathan P. Iyer is the principal investigator for this study.
- 24 Sep 2020 According to a Rhizen Pharmaceuticals Media Release, data presented in the journal Cancers.
- 24 Sep 2020 Results presented in a Rhizen Pharmaceuticals Media Release.